HWG Holdings LP Purchases 11,911 Shares of Natera, Inc. (NASDAQ:NTRA)

HWG Holdings LP lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 395.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,920 shares of the medical research company’s stock after acquiring an additional 11,911 shares during the quarter. HWG Holdings LP’s holdings in Natera were worth $1,894,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new stake in Natera during the 2nd quarter worth $28,000. Quarry LP grew its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the last quarter. Tobam acquired a new position in Natera in the second quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale bought a new position in Natera during the first quarter worth about $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the sale, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares in the company, valued at $21,211,728. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,458 shares of company stock valued at $5,924,920. Corporate insiders own 7.60% of the company’s stock.

Natera Stock Up 0.4 %

NASDAQ:NTRA opened at $119.17 on Friday. The stock has a 50-day simple moving average of $123.37 and a 200 day simple moving average of $111.09. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $133.54. The company has a market cap of $14.74 billion, a PE ratio of -48.64 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period last year, the business earned ($0.97) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price target on shares of Natera in a research note on Friday, September 13th. Morgan Stanley upped their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group lifted their price target on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Robert W. Baird upped their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, BTIG Research lifted their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.